Next, in a study that compared the Roche 454 and Ion TorrentTM PGM platforms as well as the mutation-specific platforms, Cobas® z 480 analyzer (Roche) and Rotor-Gene Q (Qiagen), Hinrichs et al. looked for KRAS and EGFR mutations in 25 FFPE samples from lung cancer patients. Here, KRAS is linked to lung carcinoma.